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Abstract
Substance use disorders is a worldwide  public health problem that commonly ocur together 
with our psychiatric and medical disorders. Along with etiologic origins, prognosis of anxi-
ety disorders intercepts with substance use disorders. Due to overlapping symptoms and 
complaints, it is always difficult for clinicians to recognise these disorders separately. In 
addition, selecting the best treatment approach is challenging because of the relative risk 
for developing anxiety disorders in substance use patients or vice versa. In this chapter, 
authors are focused on adding new aspects to the clinicians for evaluating, treating and fol-
lowing patients with comorbid substance use disorder and anxiety disorder.
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1. Introduction
Comorbidity is a medical term, implying any distinct additional clinic condition that exists 
during the progress of an index disease in a patient. Growing evidence has revealed various 
associations or interactions between many mental disorders. Nevertheless, when evolving 
diagnostic criteria and symptom diversity are taken into account, researchers developed dif-
ferent definitions in order to build a consensus among clinicians for patients meeting criteria 
for more than one mental disorder. Several authors asserted the terms “dual diagnosis”, “con-
current disorders” and “co-occurring disorders” for defining such patients, and the authors 
of this chapter will use the term “comorbidity” to indicate any anxiety disorder and any sub-
stance use disorder (SUD) co-observed in the same individual. Although there is insufficient 
data about the underlying mechanisms of psychiatric comorbidity, the presence of comorbid-
ity is generally associated with worsened prognosis, poor treatment outcomes, medication 
abuse risk and lower treatment compliance.
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativeco mons.org/licenses/by/3.0), w ich permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
As a statistical rule, disorders with high prevalence rates might be expected to be diagnosed 
in the same individual concurrently. When it comes to mental disorders, epidemiological 
studies in general population have detected a frequent occurrence pattern. Taken together, 
despite some methodological issues, anxiety disorders and substance use disorders are both 
disabling conditions, which often occur together.
2. Epidemiology
Data from clinical studies and community-based studies report a significant association 
between these disorders. In their first article derived from the results of the National Institute 
on Alcohol Abuse and Alcoholism’s National Epidemiologic Survey on Alcohol and Related 
Conditions (NESARC), Grant et al. used Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition (DSM–IV) definitions for this study and found that 12-month prevalence of 
any anxiety disorder was 11.08%, 12-month prevalence of any SUDs was 9.35% [1]. Among 
individuals with any SUDs, 17.71% had at least one independent anxiety disorder during the 
last 12-month period, and 1.46–10.54% had a specific anxiety disorder. Among participants 
with an anxiety disorders, 14.96% of them had at least one substance use disorder. Diagnosed 
with alcohol and drug use disorders increased the risk for any anxiety disorders 1.7–2.8 times. 
A few years later Grant et al. announced weighted 1-year incidence rates of any anxiety disor-
ders and any drug use disorders, as 1.57 and 0.31, respectively [2]. In their NESARC-III study, 
in which they used DSM-5 criteria, they found prevalence rates of 12-month any drug use 
disorder as 3.9% and rates of lifetime any drug use disorder as 9.9%. Also, they announced 
adjusted odd ratios for the association between 12-month drug use disorder and any anxiety 
disorder as 1.2 and 1.3 for the association between lifetime drug use disorder and any anxiety 
disorder [3]. Using data from NESARC study, Conway et al. postulated that lifetime preva-
lence rates of any anxiety disorder among people diagnosed with drug use disorders are 
higher than the general population, 29.9 versus 16.16% [4]. Compton et al. used the same data 
and announced that after adjusting for psychiatric comorbidity, odds ratios detected statisti-
cally significant only between any anxiety disorder and drug dependence [5]. According to 
Mericle et al., approximately 8.2% of white Americans, 5.8% of Latin Americans, and 5.4% of 
Black Americans 2.1% of Asian Americans met criteria for lifetime co-occurring substance use 
and mental disorders. With regard to the data composed of three different community-based 
surveys, Mericle et al. suggested that 55.4% of individuals diagnosed with any SUDs also met 
criteria for any mental disorders, and among them, any anxiety disorders were the highest 
with a co-occurance rate of 47.3% [6].
Community-based epidemiologic studies have also been conducted in other countries. In 
their latest study, derived from the data from the 2007 National Survey of Mental Health and 
Wellbeing, McEvoy et al. found no significant relationship between any anxiety disorder and 
any SUD [7]. Merikangas et al. analysed six studies from Germany, Mexico, Netherlands, 
United States and Canada and found a strong association between anxiety disorders and 
SUDs. Comorbidity rates of anxiety disorders and SUDs were different among these coun-
tries and varied between 9.9 and 56% [8]. Leray et al. announced that overall prevalence of 
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Study Sample Diagnostic tools Results
Grant et al. 2006 [1] 43,093 Americans NESARC DSM-IV (AUDADIS) In a 12-month period 17.71% 
of individuals with SUD met 
criteria for AD
Grant et al. [2] 34,653 Americans NESARC DSM-IV (AUDADIS) Weighted incidence for any 
AD is 1.57, for any SUD is 0.31. 
Low risk for comorbidity
Grant et al. [3] 36,309 Americans NESARC DSM-5 (AUDADIS) People with DUD are 1.2 
times of greater risk of having 
any AD in 12-month period, 
1.3 times of greater risk for 
lifetime
Compton et al. [5] 43,093 Americans NESARC DSM-IV (AUDADIS) Among all mental disorders in 
the study, odds ratios are only 
significant between any AD 
and drug dependence
Conway et al. [4] 43,093 Americans NESARC DSM-IV (AUDADIS) Prevalence of any AD is higher 
among individuals with DUD 
than the normal population, 
29.9 vs 16.16%
Mericle et al. [6] 20,013 US Citizens CPES DSM-IV (WMH-CIDI) Prevalence rate of any AD 
among people with SUD is 
47.3%
McEvoy et al. [7] 8841 Australians NSMHWB DSM-IV (WMH-CIDI) No significant association 
between SUD and any AD
Merikangas et al. [8] USA, n = 2874 Germany, 
n = 3021 Mexico, n = 1734 
Netherlands, n = 7076  
Ontario, n = 6902  
USA, n = 8098 ICPE
DSM-III-R Different comorbidity rates 
between AD and SUD, ranging 
from 9.9 to 56%
Leray et al. [9] 36,105 French citizens  
MHGP
MINI 3.7% of people with any AD 
met criteria for drug addiction
Toftdahl et al. [10] 463,003 Dutch citizens ICD-10 Prevalence rate of any SUDs in 
patients with AD, PTSD and 
OCD is 24.8, 17 and 11.4%, 
respectively
Lai et al. [11] 22 epidemiologic surveys Variable diagnostic methods People diagnosed with any 
SUD are of 2.9 times greater 
risk of diagnosing any AD
Only studies with epidemiologic surveys are included. NESARC, National Epidemiological Survey of Alcohol and 
Related Conditions; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; AUDADIS, 
National Institute on Alcohol Abuse and Alcoholism’s Alcohol Use Disorder and Associated Disabilities Interview 
Schedule; AD, anxiety disorder; SUD, substance use disorder; DUD, drug use disorder; DSM-5, Diagnostic and 
Statistical Manual of Mental Disorders, Fifth Edition; CPES, Collaborative Psychiatric Epidemiology Studies; 
NSMHWB, National Survey on Mental Health and Wellbeing; WMH-CIDI, World Mental Health-Composite 
International Diagnostic Interview; ICPE, International Consortium in Psychiatric Epidemiology; DSM-III-R, 
Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised Form; OCD, obsessive-compulsive 
disorder; PTSD, posttraumatic stress disorder.
Table 1. Brief information about recent population-based studies of anxiety disorders-SUD comorbidity.
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anxiety disorders in adult French population was estimated to be 21.6 and 3.7% of individuals 
with a diagnosis of an anxiety disorders also met criteria for drug addiction [9]. In a recent 
population-based study from Denmark, Toftdahl et al. established prevalence rates of SUDs 
in patients with anxiety disorders, posttraumatic stress disorder (PTSD) and obsessive-com-
pulsive disorders (OCD) as 24.8, 17 and 11.4%, respectively [10]. In a recent meta-analyses 
and systematic review in which 22 community-based studies from different countries were 
evaluated, Lai et al. found high association between illicit drug use and any anxiety disorder 
(pooled odds ratio 2.907). In other words, people with SUDs were 2.9 times of greater risk 
of having any anxiety disorder [11]. Table 1 presents the brief information about the studies 
aforementioned.
Epidemiologic studies focusing on clinical cases often examined prevalence of anxiety disor-
ders (ADs) in individuals with SUD and prevalence estimates range from 4 to 80.3%. In their 
prospective cohort study, Franken and Hendriks detected lifetime prevalence of any AD as 
Study Sample Diagnostic tools Results
Franken and Hendriks 
[12]
116 inpatients under substance 
abuse treatment
CIDI SCL-90 DSM-III-R 
ASI-Drug
Lifetime prevalence of any AD 
was 53.4%, current prevalence 
was 38.8%
Bakken et al. [13] 146 alcohol-dependent inpatients 
114 poly-substance-dependent 
inpatients
DSM-IV CIDI Weighted incidence for any AD 
is 1.57, for any SUD is 0.31. Low 
risk for comorbidity
Bakken et al. [14] 60 poly-substance abusers, 194 
alcohol-dependent patients
DSM-IV CIDI HSCL-25 48.6% of the sample met criteria 
for SAD
Sbrana et al. [15] 287 patients with various 
mental disorders, inpatient and 
outpatient setting
SCID 4% of patients with OCD also 
had DUD, 6% of the patients 
with PD also had DUD
Rosen et al. [16] 140 opiat-dependent patients  
over 50 years old
CIDI SF-12v2 27.8% of dependent patients also 
had PTSD, 29.7% of dependent 
patients had GAD
Smith and Book [17] 56 outpatients involved in 
substance abuse treatment 
program
SCID PSWQ ASI BDI Prevalence rate of any AD 
among people with SUD is 
47.3%
Goldner et al. [18] Systematic review and meta-
analysis, including 11 studies
Various diagnostic tools 29% of the patients in the studies 
met criteria for ADs and 50% of 
the participants reported anxiety 
symptoms
Only studies consisting of clinical samples are included. DSM-III-R, Diagnostic and Statistical Manual of Mental 
Disorders, Third Edition, Revised Form; ASI-Drug, ASI Drug Use Severity Composite Score; CIDI, Composite 
International Diagnostic Interview; SCL-90, Symptom Checklist-90 Revised; DSM-IV, Diagnostic and Statistical Manual 
of Mental Disorders, Fourth Edition; HSCL-25, Hopkins Symptom Checklist; SAD, social anxiety disorder; SCID, 
Structured Clinical Interview for DSM-IV; PD, panic disorder; DUD, drug use disorder; SF-12v2, Short form health 
survey; PTSD, posttraumatic stress disorder; GAD, generalised anxiety disorder; ASI, anxiety sensitivity index; BDI, 
Beck depression Inventory; PSWQ, Penn State Worry Questionnaire.
Table 2. Brief information about recent clinical studies of anxiety disorders-SUD comorbidity.
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53.4% and current prevalence of AD as 38.8% in an inpatient substance abuse population [12]. 
Bakken et al. asserted that current social anxiety disorder (SAD) diagnosis among patients with 
SUD was 51%, and this rate was higher than the alcohol-dependent patient group [13]. In their 
later study, Bakken et al. reported 48.6% of their study population met criteria for SAD [14]. 
Sbrana et al. evaluated both inpatients and outpatients diagnosed with mental disorders and 
found that 4% of the participants with OCD had drug use disorder, and 6% of the participants 
with panic disorder (PD) had drug use disorder [15]. In patients with opiate dependency, 
Rosen et al. found the prevalence of PTSD and generalised anxiety disorder (GAD) as 27.8 
and 29.7%, respectively [16]. Smith and Book analysed 56 patients with substance use disorder 
and postulated that 32% of the patient group met criteria for GAD [17]. Goldner et al. made 
a systematic review about patients with non-medical prescription opioid users and reported 
that 29% of the patients in the studies had the diagnosis of AD, and 50% of the patients were 
reporting anxiety symptoms [18]. Table 2 presents the brief information about these studies.
Current literature indicates a comorbidity between substance use disorders and anxiety dis-
orders; however, while evaluating the study results, clinicians should pay attention to some 
important issues including study designs, population or participants included in the study, 
diagnostic tools or criteria used, population size. Individuals with SUD involved in the studies 
may be in different stages of the disorder: experiencing withdrawal symptoms or abstinent, 
etc. Current diagnostic instruments are insufficiently sensitive to discriminate AD symptoms 
or substance-related symptoms, and training of the interviewers participated in the study for 
the diagnostic tools might not be standardised.
3. Development and maintenance of substance use-anxiety comorbidity
Based on search results, clinical experience and expert opinions, these disorders are both in a 
causal and etiologic relationship in both the development and maintenance of this comorbid-
ity. Different models have been developed in order to shed light to the comorbidity of anxiety 
and substance use disorders. In direct causal model, a primary psychopathology causes a 
secondary psychopathology. It has been well known that some substances including alcohol 
reduce anxiety and stress levels in a short time after they are consumed. This model is named 
as “tension-reduction” [19], “self-medication” [20] and “stress-response-dampening” [21] by 
different researchers. In all models, individuals use substances in order to reduce their anxi-
ety levels and therefore, in most of the studies evaluating AD-SUD comorbidity, results indi-
cate AD precedes the SUD. Smith and Book found GAD preceding to SUD in their study [17]. 
Having PTSD diagnosis was a risk factor for SUD, reported in a 10-year longitudinal study 
[22]. But also, according to the vulnerability hypothesis, any substance use increases anxiety 
levels and psychological arousal in time and makes the individual prone to develop PTSD 
after traumatic event or stress. Robinson et al. found evidence supporting self-medication 
theory and put forward the idea that self-medication in AD constitutes risk for developing 
SUD or vice versa [23]. Swendsen and Conway found that except GAD, ADs were predic-
tors of later drug dependence [24]. In another community-based study, SAD was found to 
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be a risk factor for cannabis dependence [25]. On the contrary, there are studies pretending 
that substance-related symptoms and/or substance withdrawal symptoms might play a role 
in the onset of AD. Using the data from a large community sample, authors claimed that 
lifetime cannabis use was found to be associated with lifetime and current panic disorder 
(PD) diagnosis, but current cannabis use was associated with only panic attacks [26]. Brady 
et al. conducted a clinic study and asserted that half of the patients had PTSD before onset 
of cocaine dependence, and the other half met criteria for cocaine dependence before PTSD 
diagnosis [27]. According to Stewart and Conrod, once the comorbidity is present, these dis-
orders pretend to serve to maintain the existence of one another. In bidirectional model, an 
individual with an AD may use substances in order to relieve symptoms of anxiety or stress. 
In time, after SUD develops, experiencing craving or withdrawal might exacerbate physical 
symptoms, and thus, panic attacks may be triggered or anticipation anxiety for the attacks 
may escalate [28].
Although epidemiological evidences are relatively determined, there is subtle data in the lit-
erature regarding biological etiology of this comorbidity. Hodgson et al. examined a sample 
of Mexican-Americans and identified a region on chromosome 18, possibly responsible for 
drug dependence and anxiety comorbidity [29].
4. Assessment and diagnosis
In the literature, assessment of comorbid mental disorders is generally performed in non-SUD 
psychiatric patients, and it is a bit more complicated to assess the comorbid mental disorders 
of patients with current diagnosis of SUD. In individuals with SUD who are applying to health 
care providers, it might be difficult for professionals to distinguish anxiety symptoms from 
the anxiety disorder. When evaluating the presenting symptoms, it is better to keep in mind 
that symptoms might be independent of the substance used, might be secondary to intoxica-
tion or withdrawal or might be due to an unidentified effect of the substance used. Diagnosing 
the comorbidity is often complicated by the anxiolytic or anxiogenic effects of the substance 
used. Being an extension of the primary/secondary disorder model, the DSM-IV and DSM-V 
classifies “substance-induced disorders (SIDs)” as a distinct diagnostic entity, which occurs 
during a period of heavy substance use or within the first 4 weeks of withdrawal. To diag-
nose a SID, symptoms should be heavier and more disabling than the symptoms expected 
to be presented in withdrawal or craving. A question may arise while evaluating a patient 
with SUD. Would diagnosing an AD in a patient with SUD require great distress and social/
occupational impairment or would endorsement of the symptoms/diagnostic criteria by the 
patient be enough for the diagnosis?
Structured Clinical Interview for DSM-V (SCID) is a semi-structured interview tool, designed 
for clinicians and interviewers with adequate training and/or clinical expertise. Having four 
different versions (clinician, personality disorders, research and clinical trials), it is offered 
to be used after a short overview and general screening of the patient. Although administra-
tion of the tool can take up to several hours, test-retest study of DSM-IV diagnoses postu-
lated excellent reliability of Axis I and Axis II diagnoses and SUDs [30]. Because established 
New Developments in Anxiety Disorders94
questionnaires and scales implemented in non-abusers might misdirect both the patient and 
the clinician. In line with this hypothesis, Kranzler et al. conducted a research in a popula-
tion with SUD and asserted that, SCID had poor validity for AD in such populations [31]. 
Kranzler et al. also asked the efficiency of the clinicians in diagnosing psychiatric disorders 
in patients with SUDs and found that clinicians using an unstructured clinical interview may 
be effective in diagnosing SUD, but, on the other hand, they may fail in diagnosing comorbid 
psychiatric disorder. They offered using SCID by trained clinicians may enhance the validity 
of both SUD diagnosis and comorbid disorders [32].
Thus, a more reliable and valid diagnostic tool for evaluating psychiatric disorders among 
substance abusers, Hasin and Grant developed the semi-structured diagnostic interview, 
Psychiatric Research Interview for Substance and Mental Disorders (PRISM) [33]. As well 
as substance use diagnosis, clinicians can use PRISM in order to evaluate current or lifetime 
diagnosis of some psychiatric disorders. Diagnostic sections of PRISM are modular, providing 
the interviewer to use it for treatment or research needs. Question patterns in the substance 
use module need gathering further and detailed information from the patient, if only the 
response is “yes” to any of them. After publication of DSM-IV, PRISM adapted to PRISM-IV, 
but one study found that the reliability of some DSM-IV ADs in the adapted form was lower 
when compared to other mental disorders [34].
Developed by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), The Alcohol 
Use Disorder and Associated Disabilities Interview Schedule (AUDADIS) is used for diagnos-
ing current or lifetime diagnoses of mood, anxiety, SUD and personality disorders. Although 
it is commonly used for population-based surveys, clinicians can use AUDADIS to tailor 
the treatment of the patient based on the responses to this schedule. Hasin et al. found this 
semi-structured interview concordant with PRISM-5 and suggested them for determining 
dimensional measures of psychopathology [35]. Developers of the tool recommend using 
computer-assisted version.
The Composite International Diagnostic Interview (CIDI), developed by World Health 
Organisation, helps clinicians in gathering information both for diagnosis and treatment 
planning. Concordance of CIDI with SCID found to be excellent for alcohol dependence, fair 
for drug dependence, good for alcohol and drug abuse [36].
The assessment of patients with AD and SUD comorbidity is a sensitive process, which 
requires a good therapeutic relationship, detailed medical history and both physical and 
psychiatric examination. Family history of any mental disorders should be interviewed and 
establishing contact with a spouse or a family member would bring contribution. Drawing 
a timeline representing the course of the psychiatric and physical symptoms and diagnosis 
would be helpful in detecting periods of exacerbation and remission.
Evaluating the patient during period of abstinence from substances is generally recom-
mended, but it can be difficult in clinical practice. Forming a retrospective timeline show-
ing both anxiety and substance use symptoms longitudinally might shed light into temporal 
sequence and the presence of anxiety symptoms during abstinence periods. Patient might 
create a prospective diary system by recording substance use and physical/mental symptoms. 
This system might help understanding which situations or emotions direct the individual to 
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substance use and whether withdrawal or craving can precipitate or exacerbate symptoms 
of anxiety. The information gathered from this diary system would also be useful for the 
clinician in formulating a treatment plan and later evaluation of the efficacy of the treatment 
interventions [37].
5. Prognosis in comorbidity
Recent evidence indicates current diagnosis of AD result in poorer treatment results and 
increased relapse risk in patients with SUD. In other words, patients who have anxious 
complaints or symptoms during or after SUD treatment might carry risks for using vari-
ous substances to alleviate anxiety symptoms. As Smith and Book reported in their study, 
GAD interferes with SUD treatment [17]. In Oumette et al.’s follow-up study, comorbid AD 
impaired engagement in SUD treatment, and comorbid AD-SUD patients had worse results 
in functioning and symptom measures when compared with patients with SUD alone. 
About 41.6% of patients with comorbid diagnosis reported significant distress [38]. Ford et 
al. reported that severity of PTSD symptoms is associated with poor contingency manage-
ment, but not standard treatment [39]. In their follow-up study, Mills et al. found no relation 
between PTSD and poor treatment initiation/completion of SUD. But also in this study, 2 
years after the beginning of treatment, PTSD symptoms remained significant and caused dis-
ability [40]. In addition to these results, Tomasson and Vaglum found better SUD treatment 
outcomes with comorbid ADs [41].
Brown et al. found that in women with PTSD, relapse occurred more rapidly than non-PTSD 
women and the authors claimed that substance using individuals with PTSD return imme-
diately to using substances to relieve their anxiety symptoms [42]. Brown also examined 
6-month outcomes of women with PTSD-SUD diagnosis, and relapse was observed at 52% of 
the patients. Twenty-four percent of the population remitted from PTSD. In this study, only 
significant predictor of substance use relapse was the severity of PTSD re-experiencing symp-
toms at attendance. Re-experiencing symptoms were also identified as predictor of PTSD sta-
tus at follow-up [43]. Oumette et al. evaluated male patients in their post-treatment period 
for 2 years and revealed that SUD-PTSD individuals had poorer treatment outcomes, and 
also SUD-only individuals were more likely to have remitted than SUD-PTSD group [44]. In 
another study by Oumette et al., they reported that attendance to the 12-Step program was 
associated with remission (defined as abstinence from all drugs, no problems associated with 
substance use and minimal alcohol use). They also emphasised that soon after discharge from 
acute SUD treatment, starting PTSD-oriented treatment was predictor of SUD remission 5 
years later [45, 46]. Taken together, PTSD-SUD individuals tend to relapse more quickly fol-
lowing SUD treatment, PTSD re-experiencing symptom severity is a predictor of relapse to 
substance use, starting the PTSD treatment soon after SUD treatment is associated with better 
substance use outcomes in 5 years.
There is limited information about PD-SUD comorbidity in the literature. In a community-
based study, among other mental disorders, PD had the greatest odd ratio for being diag-
nosed with current SUD [47]. Fals-Stewart and Schafer examined the effects of OCD diagnosis 
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on SUD, and among participants, those who took interventions for OCD had better treatment 
outcomes and had longer periods of abstinence [48]. According to Bruce et al., the presence 
of a SUD decreased the treatment outcomes of GAD by nearly fivefold and increased the 
recurrence of GAD symptoms by nearly threefold. There were no differences in treatment 
responses or recurrence rates for social phobia at 12 year follow-up period [49]. Differences 
in the results of the studies may be related to diagnostic instruments, nature of the substance 
used and duration of treatment administered.
In their systematic review, Fatseas et al. evaluated 12 studies available from the literature and 
found lifetime prevalence of anxiety disorders ranging from 26 to 35% in opiate-dependent 
patients under treatment. In opiate-dependent patients anxiety comorbidity had a complex 
and heterogeneous aetiology, but the current data recommend treating anxiety disorders in 
the first place in order to prevent opiate dependence. Among ADs in these studies, phobic 
disorders often precede the onset of opiate-dependence [50].
6. Treatment approaches
Even SUD-AD comorbidity has unfavourable outcomes, patients and families often encoun-
ter economic and systemic barriers to achieve treatment. Between 2003 and 2006, only 9–11% 
of those who could benefit from drug treatment could able to receive treatment [51]. In a 
review, current barriers to reach treatment were defined as payer financing systems, clinical 
and organisational limitations and confidentiality of patient records [52].
The most important part of treatment planning is deciding when (immediate or elective) 
and how (pharmacoterapy, psychotherapy, hospitalisation or integrated approaches) to treat 
these comorbid psychiatric conditions. Results from current studies present a complex aspect 
of the effect of the comorbidity of these disorders on treatment outcomes. The impact of AD 
diagnosis on SUD outcomes is complex that some studies suggest no significant impact on 
treatment outcomes and some suggest worse outcomes. But all of the study results agree on 
no clear negative effects of pharmacotherapy on anxiety outcomes. Also SUD treatment does 
not directly impact anxiety symptoms but in early stages of abstinence, following detoxifica-
tion, anxiety symptoms significantly decrease.
Very few studies examined the safety and efficacy of pharmacotherapy for comorbid AD-SUD 
diagnosis. Buspirone was used in a group of opiate-dependent patients under methadone 
maintenance treatment, and authors did not observe any significant improvement in anxiety 
or substance use outcomes [53]. A series of case reports about imipramine use for the treat-
ment of “phobic anxiety” SUD comorbidity postulated minor short-time improvements in 
both AD and SUD outcomes and patients who maintained the imipramine treatment for a 
long time had lower relapse to substance use rates [54]. On the other hand, later studies about 
imipramine use for cocaine and opioid dependence did not find significant benefits for the 
SUD-AD comorbidity, also when tolerability of selective serotonin reuptake inhibitors (SSRIs) 
and selective noradrenaline reuptake inhibitors (SNRIs) taken into account, they are recom-
mended as the first-line treatment approach [55, 56].
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When compared to antidepressants, benzodiazepines have the benefits of a more rapid anxio-
lytic effect, but their use in the treatment of SUD-AD has been controversial, due to concerns 
about abuse potential. In parallel with these concerns, there is a few literature examining the 
efficacy of safety of benzodiazepines in the treatment of AD-SUD [55]. Also, there are data in 
the literature suggesting that people with a personal and family history of SUDs may be more 
susceptible to addictive potential of benzodiazepines and thus might carry greater risk of 
medication abuse [56, 57]. Additionally, benzodiazepine misuse is more common in patients 
with SUD, especially among those with a diagnose of more sever SUD, polysubstance users 
and greater psychiatric comorbidity [58]. Despite all, a case series about using benzodiaz-
epines for AD-SUD suggested that benzodiazepines were able to sustain abstinence when 
patients were selected carefully and monitored closely [59].
Until well-controlled studies are conducted, safety and efficacy of benzodiazepines for this 
population will remain unknown. Therefore, alternative therapies with better safety and effi-
cacy profiles are recommended as the first-line therapeutic approach. Considering benzodiaz-
epines is recommended only after these treatment options are ineffective [56, 59].
Studies have also evaluated the effect of some pharmacotherapeutic agents for comorbid 
AD-SUD. Topiramate, modulating principally gamma-amino butyric acid (GABA) and gluta-
mate-mediated neurons, has been presumed as a treatment for cocaine dependence [60]. Also, 
there are studies suggesting topiramate as an effective treatment option in certain ADs such as 
SAD [61], OCD [62] and PTSD [63]. Also, studies about another GABA-ergic agent tiagabine, 
which has been shown to be effective in the treatment of some ADs, have conflicting results 
about the treatment of SUDs [64].
After reviewing general treatment considerations, authors would like to present acknowl-
edgement about each anxiety disorder in the light of the current literature.
7. Post traumatic stress disorder
Epidemiologic studies indicate high comorbidity rates for PTSD-SUDs. The NESARC study 
found lifetime prevalence as 6.4 and 46.4% of people with PTSD met criteria for any SUD 
and 22.3% of them met criteria for substance dependence [65]. Based on the data from the 
Australian National Survey of Mental Health and Well-Being survey, 34.4% of individuals 
diagnosed with PTSD had at least one SUD, generally more than one SUD [66]. In clinical 
settings, when compared to patients without PTSD, patients with PTSD found to be 14 times 
more likely met criteria for SUD [67]. Rates of lifetime PTSD in treatment-seeking SUD popu-
lations range from 30 to 60% [68]. Studies about PTSD-SUD comorbidity indicate earlier onset 
of substance use, more polysubstance use, more cognitive distortions, more comorbid mental 
disorders, more frequent self-destructive behaviour and increased vulnerability to revictimi-
sation [69].
Studies trying to define neurobiological mechanisms underlying this comorbidity focused 
on hypothalamic-pituitary-adrenal (HPA) axis and noradrenergic system. In the cerebro-
spinal fluid of individuals with PTSD, levels of corticotropin releasing factor (CRF) and 
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norepinephrine were detected higher than normal levels. Considering the role of CRF and 
norepinephrine as a mediator of the relationship between stress and substance seeking 
behaviour, future research about these might explain “self-medication of PTSD symptoms 
using substances” theory in some individuals [70].
Although current knowledge suggests concurrent and integrated treatment strategies for 
patients with comorbid PTSD-SUD, studies about medications in the treatment of this comor-
bidity are lacking. In a prospective observational study, opioid replacement therapy was 
found to be effective at reducing substance use in patients with opioid dependence and PTSD. 
However, patients with comorbidity received higher doses of opioid medication and attended 
more psychosocial treatment sessions when compared to SUD-only group [71].
N-acetylcysteine (NAC), a derivative of the dietary amino acid cysteine, is used as a mucolytic 
agent for pulmonary diseases and used for acetaminophen toxicity. Providing an increase 
in the production of glutathione, it is supposed to restore substance-related glutamatergic 
dysregulation, and a study has shown its modest efficacy in reducing cocaine use and craving 
[72]. There are randomised controlled trials exploring its efficacy versus placebo in the treat-
ment of SUD-PTSD comorbidity.
With the recent studies, the neuropeptide oxytocin has become a favourable treatment option 
in many psychiatric disorders. Because oxytocin is supposed to have anxiolytic and fear-mod-
ulating effects, it becomes a promising treatment option to augment exposure-based thera-
pies for PTSD-SUD comorbidity [73]. Furthermore, with regard to neuroimaging studies, it 
is postulated that oxytocin might mitigate the dysregulation of corticolimbic brain circuitry, 
a neurobiological mechanism underlying SUD-AD comorbidity [74]. Current literature indi-
cates that combining oxytocin treatment with psychosocial interventions may improve the 
treatment outcomes of this comorbidity.
Psychosocial treatment approaches can basically divide into non-exposure-based and expo-
sure-based treatments. Seeking Safety (SS) aims to educate patients about decreasing risky 
behaviours, coping with substance triggers, developing self-control skills and enhancing 
communication skills to build a supportive environment. Transcend is an eclectic, 12-week 
partial hospitalisation group program and consists of 12-step treatment programs, cogni-
tive behavioural therapy (CBT), psychodynamic and constructivist interventions. CBT for 
PTSD has an 8–12 session protocol that focuses on breath training, psycho-education and 
coping skills (e.g. cognitive restructuring and relapse prevention). Among these treatment 
approaches, researchers have been studied SS most thoroughly. But, there is no evidence sup-
porting any significant positive effects of non-exposure-based treatments in the treatment of 
PTSD-SUD comorbidity [75].
Exposure-based psychosocial treatment approaches include prolonged exposure and concur-
rent treatment of PTSD and cocaine dependence. Prolonged exposure (PE) includes psycho-
education, breathing training, in vivo exposure and imaginal exposure. Concurrent treatment 
of PTSD and cocaine dependence (CTPCD) is a 16-session treatment program. In first 5 ses-
sions patients complete coping skills training, learn PTSD-focused psycho-education and PE 
treatment rationale. After one session focusing on imaginal and in vivo exposure, coping skills 
treatment is continued throughout the treatment protocol. According to a systematic review 
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by Dam et al., exposure-based psychosocial treatment interventions might be more promising 
in concurrent treatment for PTSD-SUD comorbidity [75].
8. Panic disorder
Lifetime prevalence of panic disorder was 4.7%, and 12-month prevalence of panic disorder 
was 2.7% in United States [76]; people with lifetime SUD diagnosis were found to be 1.3 times 
more likely to meet criteria for panic disorder [3]. But there is no study or case report in the 
literature about the treatment of PD-SUD comorbidity.
9. Social anxiety disorder
According to NESARC data, prevalence rate of SAD-SUD comorbidity is 2.4% in general 
population [77]. Book et al. found that the presence of SAD had a significant negative effect 
on treatment motivation [78]. In their later study, they also postulated that there were no 
differences in the anxiety levels of people seeking treatment with comorbid SAD-SUD and 
SAD-only, but they also suggested the clinicians to be aware of the difficulties in engaging 
SAD-SUD patients in social communications [79]. There is only one case report about phar-
macotherapeutic approach of SAD-SUD, and gabapentin was found to be effective in a patient 
with SAD-SUD comorbidity [80].
10. Obsessive-compulsive disorder
There is not much study in the literature about OCD-SUD comorbidity. In their study, 
False-Stewart and Schafer found that symptoms of OCD were subtle for the patient, and 
the patients might have the tendency to hide their symptoms. They also postulated inte-
grated OCD/SUD physchotherapeutic interventions as an effective treatment approach for 
the comorbidity [48].
11. Generalised anxiety disorder
People with lifetime SUD diagnosis were found to be 1.3 times more likely to meet criteria 
for GAD [3], and the presence of GAD has a negative impact on treatment outcomes. Because 
GAD symptoms may be similar to the symptoms of intoxication or withdrawal, it is recom-
mended to delay assessment of GAD until this period ends. No clinical trials of pharmaco-
therapuetic interventions on GAD-SUD have been conducted.
There are no data available in the literature about the comorbidity of novel psychoactive sub-
stances (synthetic cannabinoids, designer drugs, etc.) use and any anxiety disorder. Acute or 
chronic use of some of these substances is associated with anxiety symptoms and some people 
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with anxiety disorders use these substances in order to relieve their complaints. Basically, this 
mutual relationship might be perceived as common etiologic origins but well-designed stud-
ies about this comorbidity should be conducted in the recent future.
12. Conclusion
In the last few decades, the close relationship between SAD and SUD has been well-docu-
mented. After then, research has focused on diagnosing comorbidity and tailoring treatment 
for the index patients. Today, most of the patients have the opportunity to receive treatment 
from both mental and addiction services. Sometimes patients are directed from one clinic to 
the other based on the current presenting symptoms of referral.
Although patients with SUD-AD comorbidity face with increased distress, social/occupa-
tional impairment and complicated clinical course, there is limited knowledge about effective 
treatment approaches. Future research should focus on developing integrated psychosocial 
treatments and pharmacological interventions. Discovering underlying neurobiologic mecha-
nisms may help clinicians better understand prognostic and diagnostic parameters of this 
pathophysiology and treatment outcomes.
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